| omega-3 ethylester concentrate / Generic mfg. |
2004-004404-21: Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences |
|
|
| Ongoing | 4 | 60 | Europe | Omacor, Capsule, soft, Omacor | GreenPark Healthcare Trust, Queens University Belfast | Systemic Lupus Erythematosus | | | | |
2013-004750-24: Fish oil in surgery for obesity, effects on liver volume, immune response and red blood cell function Visolie bij chirurgie wegens obesitas, effect op de grootte van de lever, de afweerreactie rondom de operatie en op de functie van de rode bloedcel |
|
|
| Ongoing | 4 | 62 | Europe | Omega 3-acid-ethyl esters 1000mg Soft Capsules, C10AX06, Capsule, soft, Omega-3 fatty acids | Rode Kruis Ziekenhuis, Rode Kruis Ziekenhuis | Patients qualified for bariatric surgery Patiënten die in aanmerking komen voor een Roux-en-Y maagomleiding, Patients qualified for surgery for obesity Patienten die in aanmerking komen voor een maagverkleining vanwege obesitas, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2005-001332-69: A randomised control trial of omega-3 fatty acid on platelet and endothelial function in patients with peripheral arterial disease |
|
|
| Ongoing | 4 | 150 | Europe | OMACOR, N/A, OMACOR, OMACOR | University of Aberdeen | Intermittent claudication | | | | |
2005-001354-25: Use of Omega-3 poyunsaturated Fatty Acid Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation:a prospective and randomised study. |
|
|
| Ongoing | 4 | 150 | Europe | Omega-3, PL15905/0001, Omacor, Omacor | University of Dundee | Patients with persistent atrial fibrillation | | | | |
2005-002688-10: The Effect of omega-3 polyunsaturated Fatty Acid Supplements on Microvolt T-Alternans in Patients with Ventricular Arrythmia |
|
|
| Ongoing | 4 | 45 | Europe | Omega-3, PL15905/0001, Omacor, Omacor | University of Dundee | Patients with Implantable Cardioverter Defibrillator(ICD) with ventricular arrythmias | | | | |
2006-001451-35: How does fish oil supplementation protect against atrial fibrillation following coronary artery by-pass surgery? - A cellular study. |
|
|
| Ongoing | 4 | 300 | Europe | OMACOR, Omacor, Omacor | South Manchester University NHS Trust | ATRIAL FIBRILLATION (AF) FOLLOWING CORONARY ARTERY BY-PASS GRAFT (CABG)SURGERY. | | | | |
2008-000330-50: EFECTO DE SUPLEMENTACIÓN NUTRICIONAL ENRIQUECIDA CON ÁCIDOS GRASOS OMEGA-3 EN EL ESTRÉS OXIDATIVO Y METABOLISMO LIPÍDICO DE PACIENTES CON PROCESOS ONCOLÓGICOS DEL ÁREA OTORRINOLARINGOLÓGICA (ORL) SOMETIDOS A RADIOTERAPIA |
|
|
| Ongoing | 4 | 50 | Europe | PROSURE, OMACOR, ISOSOURCE ® Protein, RESOURCE ® 2.0, PROSURE, OMACOR, ISOSOURCE ® Protein, RESOURCE ® 2.0 | Organisation name was not entered | Determinar las modificaciones inducidas por la suplementación especifica de ácidos grasos omega3 en el estrés oxidativo y estado inflamatorio en pacientes oncológicos sometidos a tratamiento radioterápico. El presente proyecto es un estudio prospectivo con un año de seguimiento de dos pautas de intervención nutricional administradas de forma aleatoria. | | | | |
2008-008517-19: Estudio multicéntrico controlado y aleatorizado sobre la eficacia de los ácidos grasos poliinsaturados (Omacor R) en la mejoría clínica y la prevención del síndrome metabólico en pacientes con esquizofenia. |
|
|
| Ongoing | 4 | 300 | Europe | OMACOR 1000 mg cápsulas blandas, OMACOR 1000 mg cápsulas blandas | CONSORCI SANITARI DEL MARESME | Esquizofrenia . Mejora de síntomas clínicos y del Síndrome Metabólico asociado al uso de antipsicóticos. | | | | |
2005-000778-31: OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE: EFFECTS ON ENDOTHELIAL FUNCTION, LEFT VENTRICULAR REMODELLING, NATRIURETIC PEPTIDE LEVELS, AND EXERCISE CAPACITY |
|
|
| Ongoing | 4 | 145 | Europe | Omacor, 1-21530, Omacor, Omacor | Dept. of Cardiology, Medical University of Vienna | chronic heart failure | | | | |
| Active, not recruiting | 4 | 15480 | Europe | Aspirin, Omega-3 Ethyl Esters, n-3 fatty acid, Omacor, Placebo Aspirin, Placebo Omega-3 Ethyl Esters | University of Oxford, British Heart Foundation, Bayer, Medical Research Council, Solvay Pharmaceuticals, Abbott, Mylan, Health Data Research UK, Alzheimer's Research UK, The Macular Society | Diabetes Mellitus | 03/18 | 07/37 | | |
ChiCTR2200060027: A randomized, double-blind, effective, prospective randomized controlled clinical trial: to investigate the effects of Omega-3 polyunsaturated fatty acids on glycosylated hemoglobin and islet α and β cells in patients with type 1 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 84 | | Placebo (corn oil) ;Omega-3 fatty acid ethyl ester 90 soft capsule (trade name: Lilexin) | The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat-Sen University, Gowell Pharma | Type 1 diabetes mellitus (T1DM) | | | | |
2010-023071-25: cambios en la densitometrÃa mineral ósea en pacientes infectados por VIH. Estudio aleatorizado con ácidos grasos poliinsaturados n-3.changes in bone mineral densitometry HIV-infected patients. Randomized study with polyunsaturated fatty acids n-3 |
|
|
| Ongoing | 3 | 60 | Europe | Capsule, soft, OMACOR 1000 mg cápsulas blandas | Daniel Podzamczer Palter | La enfermedad investigada es el VIH, se administrará el fármaco a pacientes que presenten hipertrigliceridémia secundaria a los TARGA y se evaluaran los efectos del MI sobre el metabolismo óseo, que también se ve afectado por los TARGA.The HIV disease is investigated, the drug is administered to patients with hypertriglyceridemia secondary to HAART and evaluating the effects of MI on bone metabolism, which also is affected by HAART. | | | | |
| Ongoing | 3 | 400 | Europe | Omacor, Aspirin protect 100mg, Omacor Omega-3 ethyl esters 90, Aspirin® protect 100 mg, Omacor Omega-3 ethyl esters 90, Aspirin® protect 100 mg | Australian Kidney Trials Network, University of Queensland, NHMRC | Early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis | | | | |
EMiRA, NCT03018041: The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation |
|
|
| Active, not recruiting | 3 | 174 | Europe | Omacor, Omega-3 fatty acids, EPA, DHA, Marine n-3 polyunsaturated fatty acids, Placebo Oral Capsule, Olive oil | Joe Chan, University of Oslo, Rikshospitalet University Hospital, Ullevaal University Hospital, Drammen sykehus, Elverum Hospital, South-Eastern Norway Regional Health Authority, Aalborg University Hospital, Pronova BioPharma, Haukeland University Hospital, University Hospital of North Norway | Kidney Transplantation | 08/25 | 08/25 | | |
| Terminated | 2/3 | 1 | US | Lovaza, omega-3 fatty acids, omega-3-acid ethyl esters, L-Arginine Powder, Arginine, 2-amino-5-guanidinopentanoic acid, Vitamin C, Ascorbic acid | Prisma Health-Midlands | Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer | 03/23 | 03/23 | | |
2006-004335-29: A randomised controlled factorial pilot study investigating Omacor and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy. |
|
|
| Ongoing | 2 | 72 | Europe | Omacor, Lescol, Omacor, Lescol | Newcastle Upon Tyne Hospitals NHS Foundation Trust | Chronic Hepatitis C Infection | | | | |
2009-011819-20: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study. |
|
|
| Ongoing | 2 | 6 | Europe | OMACOR, OMACOR | Pierre Fabre Médicament | Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD). | | | | |
MIRACLE, NCT04907864: Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management |
|
|
| Recruiting | 2 | 112 | RoW | Multi-modal intervention, ibuprofen (Brufen), omega-3-fattyacid (Omacor), Bojungikki-tang (Kracie Bojungikgitang Extract Fine Granule), oral nutritionalsupplement (HARMONILAN SOLN) | Kil Yeon Lee, National Research Foundation of Korea | Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Lung Cancer, Precachexia, Cachexia | 03/22 | 06/22 | | |
COLYNE, NCT03831698: Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome |
|
|
| Active, not recruiting | 2 | 21 | US | Omega-3 fatty acid ethyl esters (2 gram), lovaza | University of Kansas Medical Center | Colorectal Cancer, Lynch Syndrome | 06/22 | 08/24 | | |
| Completed | 2 | 77 | US | Omega-3 fatty acid supplement, Lovaza | University of Michigan Rogel Cancer Center | Breast Cancer | 02/24 | 02/24 | | |
NCT06434948: The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery |
|
|
| Not yet recruiting | 2 | 90 | NA | Omega-3 Ethyl Esters 4 g, Omega-3 ethyl esters, Lovaza, Omega-3 Ethyl Esters 2 g | University of Missouri-Columbia | Postoperative Delirium | 06/25 | 06/25 | | |
NCT06195306: Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction |
|
|
| Not yet recruiting | 2 | 66 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Mammography, MG, Omega-3-Acid Ethyl Esters, Lovaza, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Random Periareolar Fine Needle Aspiration, RPFNA, Tamoxifen, TMX | National Cancer Institute (NCI) | Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ | 01/27 | 01/27 | | |
NCT03598309: Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers |
|
|
| Recruiting | 2 | 75 | US | Curcumin C3 complex®, Curcuminoid, Lovaza®, Omega-3-Acid Ethyl Esters, Placebo, Pill with no drug or other active ingredients in it. | H. Lee Moffitt Cancer Center and Research Institute, James and Esther King Biomedical Research Program | Lung Diseases, Lung Cancer, Protection Against | 12/24 | 12/24 | | |
NCT01233856: Omega-3 Fatty Acids as an Adjunctive Therapy for Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) |
|
|
| Recruiting | N/A | 30 | US | Lovaza, Placebo (corn oil). | Maimonides Medical Center, GlaxoSmithKline | Attention-Deficit/Hyperactivity Disorder | 06/12 | 06/12 | | |
| No Longer Available | N/A | | US | Lovaza (Fish Oils), Lovaza NDA021654, Omacor NDA021853 | St. Luke's-Roosevelt Hospital Center, GlaxoSmithKline | Atrial Fibrillation | | | | |
| Active, not recruiting | N/A | 25871 | US | Vitamin D3, Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol, fish oil, Omacor; 1 g per day as a fish oil capsule, containing 840 milligrams of marine omega-3 fatty acids (460 mg of eicosapentaenoic acid [EPA] and 380 mg of docosahexaenoic acid [DHA])., Vitamin D3 placebo, Fish oil placebo | Brigham and Women's Hospital, Harvard School of Public Health (HSPH) | COPD, Asthma, Pulmonary Function, Pneumonia | 11/18 | 02/25 | | |
NCT01782352: Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL) |
|
|
| Active, not recruiting | N/A | 25871 | US | Omega-3 fatty acids (fish oil), Omacor, Vitamin D3, cholecalciferol, Vitamin D3 placebo, Fish oil placebo | Brigham and Women's Hospital, National Eye Institute (NEI) | Age-related Macular Degeneration | 12/19 | 09/24 | | |
| Active, not recruiting | N/A | 600 | US | Vitamin D3 (cholecalciferol), 2000 IU per day, omega-3 fatty acids (fish oil), Omacor, 1 capsule a day., Each capsure of Omacor contains 840 milligrams of marine omega-3 fatty acid, (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]). | Brigham and Women's Hospital, American Heart Association | Adiposity | 07/22 | 07/22 | | |
| Active, not recruiting | N/A | 25875 | US | Vitamin D3, cholecalciferol, Omega-3 fatty acid (fish oil), fish oil, eicosapentaenoic acid, docosahexaenoic acid, EPA, DHA, Omacor®, Vitamin D3 placebo, Fish oil placebo | Brigham and Women's Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes | 05/24 | 05/24 | | |